HDAC9 and neurodegenerative disease: The present review is devoted to the analysis of publications over the past two years in the field of HDAC inhibitors intended for the monotherapy of not only cancer but also neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease), diseases of the cardiovascular system, liver, lungs, and psoriasis.